Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.44 |
| ▸ | ASPH | Q12797 | 1/20 | 0.44 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | THRB | P10828 | 4/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30222084 | 1.00 | KEAP1 (0.50) | KEAP1KDM4EASPHKDM8KMT2A | |
| SCHEMBL99199 | 0.91 | KEAP1 (0.50) | KEAP1KDM4EASPHKDM8KMT2A | |
| SCHEMBL24338031 | 0.88 | KEAP1 (0.52) | KEAP1KDM4EASPHKDM8KMT2A | |
| Ammonia Solution, Strong SCHEMBL15377820 | 0.86 | KEAP1 (0.50) | KEAP1KDM4EASPHKDM8KMT2A | |
| SCHEMBL5872835 | 0.83 | KDM4E (0.52) | KEAP1KDM4EASPHKDM8KMT2A | |
| SCHEMBL17774712 | 0.83 | ALDH1A1 (0.48) | KEAP1KDM4EKMT2AGFERRXFP1 | |
| SCHEMBL19834110 | 0.83 | KEAP1 (0.47) | KEAP1KDM4EASPHKDM8KMT2A | |
| SCHEMBL3086937 | 0.82 | DGAT1 (0.48) | KEAP1KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL21050064 | 0.81 | CA12 (0.47) | KEAP1KDM4EASPHKDM8KMT2A | |
| SCHEMBL10324220 | 0.81 | KEAP1 (0.46) | KEAP1KDM4EASPHKDM8KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159564-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | iTeos Belgium SA (BE) | 2023-05-25 | — | — | US | disclosed |
| US-20230159564-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | iTeos Belgium SA (BE) | 2023-05-25 | — | — | US | disclosed |
| US-20230159564-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | iTeos Belgium SA (BE) | 2023-05-25 | — | — | US | disclosed |
| US-11634390-B2 | Agricultural chemicals | GLOBACHEM NV (BE) | 2023-04-25 | — | — | US | disclosed |
| CN-115991679-A | 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer | 伊忒欧斯比利时股份公司 | 2023-04-21 | — | — | CN | disclosed |
| WO-2023062627-A1 | HERBICIDES AND USE THEREOF | PROJINI AGCHEM LTD (IL) | 2023-04-20 | — | — | WO | disclosed |
| CN-115873022-A | 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer | 伊忒欧斯比利时股份公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20230098694-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | ITEOS BELGIUM S A (BE) | 2023-03-30 | — | — | US | disclosed |
| CN-110678472-B | 2-oxothiazole derivatives as A2A inhibitors and compounds for the treatment of cancer | 伊忒欧斯比利时股份公司 | 2023-01-24 | — | — | CN | disclosed |
| EP-4112623-A1 | 2-OXO-THIAZOLE DERIVATIVES AS A2A INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2023-01-04 | — | — | EP | disclosed |
| US-7084160-B2 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060135576-A1 | Heterocyclic inhibitors of kinases | BORZILLERI ROBERT M | 2006-06-22 | — | — | US | disclosed |
| US-20050234060-A1 | Pyrrolotriazine kinase inhibitors | BHIDE RAJEEV S | 2005-10-20 | — | — | US | disclosed |
| US-6951859-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1543009-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1513818-A2 | HETEROCYCLIC INHIBITORS OF KINASES | Bristol-Myers Squibb Company (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040077696-A1 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004013145-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004001059-A2 | HETEROCYCLIC INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135576-A1 | Heterocyclic inhibitors of kinases | FGFR1, FLT1, FGFR2 | KEAP1 1216/4885KDM4E 1669/4885ASPH 1964/4885 |
| US-20230098694-A1 | NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS | ADORA2A, ADORA2B, ADORA1 | KEAP1 2160/4885KDM4E 2990/4885ASPH 2501/4885 |
| US-20040077696-A1 | Heterocyclic inhibitors of kinases | FGFR1, FLT1, FGFR2 | KEAP1 1290/4885KDM4E 2184/4885ASPH 2227/4885 |
| US-20230159564-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | ADORA2A, ADORA2B, ADORA3 | KEAP1 1045/4885KDM4E 3152/4885ASPH 3392/4885 |
| US-20040063708-A1 | Pyrrolotriazine kinase inhibitors | FGFR1, FLT1, FGFR2 | KEAP1 1908/4885KDM4E 1969/4885ASPH 2067/4885 |
| US-11634390-B2 | Agricultural chemicals | DDT, DHFR, AS3MT | KEAP1 69/4885KDM4E 789/4885ASPH 243/4885 |
| US-20050234060-A1 | Pyrrolotriazine kinase inhibitors | FGFR1, FLT1, FGFR2 | KEAP1 1806/4885KDM4E 2156/4885ASPH 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.